A novel Bcl-2/Bcl-XL inhibitor APG-1252-12A as a potential therapeutic strategy for gastric carcinoma

被引：0
|
作者：
Yan, Xianglei [1 ]
Yi, Hanjie [1 ]
Luo, Qiuyun [1 ]
Yuan, Luping [1 ]
Zhou, Suna [1 ]
Pan, Wentao [2 ]
Zhang, Lin [1 ]
Qiu, Miaozhen [1 ]
Yang, Dajun [1 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Guangdong, Peoples R China
[2] Ascentage Pharma Inc, Suzhou, Peoples R China
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-2054
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2054
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck
    Pena, JC
    Thompson, CB
    Recant, W
    Vokes, EE
    Rudin, CM
    CANCER, 1999, 85 (01) : 164 - 170
  • [22] A novel Bcl-2/Bcl-XL/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma
    D Chauhan
    M Velankar
    M Brahmandam
    T Hideshima
    K Podar
    P Richardson
    R Schlossman
    I Ghobrial
    N Raje
    N Munshi
    K C Anderson
    Oncogene, 2007, 26 : 2374 - 2380
  • [23] Bcl-XL and Bcl-2 expression in squamous cell carcinoma of the head and neck
    Budach, W
    STRAHLENTHERAPIE UND ONKOLOGIE, 1999, 175 (10) : 533 - 534
  • [24] Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2
    Yoshihito Morimoto
    Kimihiko Takada
    Osamu Takeuchi
    Kazuhiro Watanabe
    Masayoshi Hirohara
    Tomoyuki Hamamoto
    Yutaka Masuda
    Molecular and Cellular Biochemistry, 2020, 472 : 187 - 198
  • [25] Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition
    Pal, Pratik
    Thummuri, Dinesh
    Lv, Dongwen
    Liu, Xingui
    Zhang, Peiyi
    Hu, Wanyi
    Poddar, Saikat K.
    Hua, Nan
    Khan, Sajid
    Yuan, Yaxia
    Zhang, Xuan
    Zhou, Daohong
    Zheng, Guangrong
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (19) : 14230 - 14246
  • [26] Mtd, a novel Bcl-2 family member activates apoptosis in the absence of heterodimerization with Bcl-2 and Bcl-XL
    Inohara, N
    Ekhterae, D
    Garcia, I
    Carrio, R
    Merino, J
    Merry, A
    Chen, S
    Núñez, G
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (15) : 8705 - 8710
  • [27] Discovery and therapeutic potential of novel Bcl-2/Bcl-xL small-molecule inhibitors in human breast cancer.
    Xu, L
    Wang, G
    Tang, N
    Nikolovska-Coleska, Z
    Wang, R
    Demchik, L
    Liu, M
    Zhang, M
    Roller, P
    Tomita, Y
    Yang, D
    Rae, J
    Lippman, ME
    Wang, S
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S66 - S66
  • [28] Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2
    Morimoto, Yoshihito
    Takada, Kimihiko
    Takeuchi, Osamu
    Watanabe, Kazuhiro
    Hirohara, Masayoshi
    Hamamoto, Tomoyuki
    Masuda, Yutaka
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2020, 472 (1-2) : 187 - 198
  • [29] Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway
    Fan Luo
    Fei-Teng Lu
    Miao-Zhen Qiu
    Ting Zhou
    Wen-Juan Ma
    Min Luo
    Kang-Mei Zeng
    Qiu-Yun Luo
    Wen-Tao Pan
    Lin Zhang
    Zeng-Fei Xia
    Zhong-Han Zhang
    Jia-Xin Cao
    Hong-Yun Zhao
    Li Zhang
    Da-Jun Yang
    Cell Death & Disease, 12
  • [30] Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway
    Luo, Fan
    Lu, Fei-Teng
    Qiu, Miao-Zhen
    Zhou, Ting
    Ma, Wen-Juan
    Luo, Min
    Zeng, Kang-Mei
    Luo, Qiu-Yun
    Pan, Wen-Tao
    Zhang, Lin
    Xia, Zeng-Fei
    Zhang, Zhong-Han
    Cao, Jia-Xin
    Zhao, Hong-Yun
    Zhang, Li
    Yang, Da-Jun
    CELL DEATH & DISEASE, 2021, 12 (08)
12345